Verismo Therapeutics announced that is has received clearance of its new drug for ovarian cancer, cholangiocarcinoma, and, mesothelioma from the U.S. Food and Drug Administration (FDA) to initiate a first-in-human Phase 1 clinical trial of SynKIR-110.
The first human trials are set to start soon. They will “address several areas of high unmet medical need.” The five-year survival rates are 49.7% for ovarian cancer, 30% for cholangiocarcinoma and 10% for mesothelioma.
The FDA’s clearance of the new drug represents a new for mesothelioma treatments and innovative research.
Verismo plans to begin enrolling patients in the first quarter of 2023 at the initial clinical site, the Hospital of the University of Pennsylvania.